verapamil has been researched along with oseltamivir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Doi, H; Kanai, M; Kusuhara, H; Mizuma, H; Morita, M; Nagata, H; Onoe, H; Onoe, K; Shibasaki, M; Sugiyama, Y; Takahashi, K; Takashima, T; Tazawa, S; Wada, Y; Watanabe, Y; Yamanaka, H; Yokoyama, C | 1 |
1 review(s) available for verapamil and oseltamivir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for verapamil and oseltamivir
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.
Topics: Aging; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Calcium Channel Blockers; Carbon Radioisotopes; Enzyme Inhibitors; Injections, Intravenous; Macaca mulatta; Male; Neuraminidase; Oseltamivir; Positron-Emission Tomography; Radiopharmaceuticals; Verapamil | 2011 |